You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Financial news, mergers and acquisitions, partnerships, and alliances.
The firm won't have to pay off its unsecured convertible notes until 2026 to investors, including Patrick Soon-Shiong's Nant Capital.
The UK-based firm aims to begin evaluating kidney disease biomarkers in expanded clinical validation studies later this year.
The Swiss company said it will use the funding to accelerate commercialization of its blood-based calcification propensity test for kidney disease patients.
DiaSorin said that the acquisition gives it access to Luminex's multiplexing technology, tests, and instruments and strengthens its MDx product portfolio.
The company said it expects revenue growth to be approximately 57 percent year over year and non-GAAP core revenue growth to be approximately 29 percent.